How much does a box of Rucaparib cost? market price

Rucaparib (Rucaparib), as a new type of PARP inhibitor, has been launched in Europe and the United States and other countries and regions, and has been included in the treatment plan for ovarian cancer and some prostate cancers. Its application is mainly reflected in the field of precision medicine, especially for tumor types with BRCA mutations or DNA repair defects. Rucaparib provides a new treatment option for patients who have received multiple lines of chemotherapy and have relapsed. In terms of treatment strategy, the drug can be used as a single-agent treatment after recurrence or as a maintenance treatment for patients sensitive to platinum chemotherapy, thereby helping to delay tumor progression and improve patients' quality of life.

In the Chinese market, rucapanib has not yet been approved for marketing, so there is no medical insurance reimbursement policy and it cannot be purchased in regular domestic pharmacies or hospitals. If patients need medicine, they usually need to obtain it through cross-border medical channels. According to overseas public information, the specification of the original drug Rucapani listed in the EU is 300mg*60 tablets, and the price is about RMB 38,000. This pricing level is not uncommon among innovative tumor-targeted drugs, but due to the lack of generic drugs, its price will be difficult to drop in the short term. Compared with some PARP inhibitors that have been on the market for many years, the cost of rucapanib is still high, which is also one of the important factors limiting its popularity worldwide.

From the perspective of the international market structure, the supply of rucapanib in the United States, Europe and other places is relatively stable, and prices fluctuate due to the impact of the medical system, medical insurance reimbursement, and exchange rates. In contrast, domestic patients have lower accessibility to the drug in the short term and a heavier financial burden.

For patients with potential indications, the clinical significance of rucapanib is not only to prolong progression-free survival, but also to provide a new treatment idea with a new mechanism. Although the current market price is relatively high, with the advancement of policy guidance and the development of generic drugs, rucapanib is expected to become affordable for more patients in the future.

Reference materials:https://www.drugs.com/mtm/rucaparib.html